Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $101,417.10 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,174 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total transaction of $101,417.10. Following the completion of the transaction, the insider directly owned 113,549 shares of the company’s stock, valued at approximately $5,297,060.85. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The stock was sold at an average price of $43.95, for a total transaction of $13,668.45.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $45.00, for a total transaction of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.61, for a total transaction of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total transaction of $302,524.95.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $42.60 on Friday. The firm has a market cap of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $48.61. The company has a fifty day moving average price of $32.83 and a 200 day moving average price of $32.94.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The firm had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.47) EPS. Research analysts predict that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Wall Street Analyst Weigh In

Several brokerages have commented on TVTX. Guggenheim boosted their price target on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target on the stock in a research report on Tuesday, April 14th. JPMorgan Chase & Co. cut their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Wedbush boosted their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Weiss Ratings cut shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Travere Therapeutics by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock valued at $158,059,000 after purchasing an additional 619,085 shares during the period. State Street Corp raised its holdings in shares of Travere Therapeutics by 47.8% in the 4th quarter. State Street Corp now owns 4,756,666 shares of the company’s stock valued at $181,752,000 after purchasing an additional 1,538,827 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after purchasing an additional 483,565 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Travere Therapeutics by 27.4% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after acquiring an additional 599,102 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Travere Therapeutics by 28.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock worth $85,849,000 after acquiring an additional 494,665 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.